Immunotherapy plus chemo before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of immunotherapy (toripalimab) with two chemotherapy drugs before surgery for esophageal cancer, compared to a standard chemo regimen. The goal is to see if the new combination improves outcomes for patients with resectable tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with squamous cell carcinoma of the esophagus that can be removed with surgery
- Your cancer has not spread to distant organs
- You have not had previous treatment for this cancer
- You are in good overall health (able to care for yourself, adequate organ function)
- You agree to use effective contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, and low-dose radiation for people with esophageal cancer that did not shrink after initial chemotherapy and immunotherapy. The goal is to see if this new combination can help control the cancer before surgery.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests whether continuing a type of immunotherapy (toripalimab) after standard chemoradiation helps keep advanced esophageal cancer from growing, compared to just watching and waiting. If you've already completed initial treatment without the cancer getting worse, this study might help you stay stable longer.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.